Merck to Acquire EyeBio for Up to $3B

Rahway, NJ, and New York, May 29, 2024 (Business Wire) -- Merck is acquiring EyeBio, a biotech company focused on eye diseases, in a deal potentially worth $3 billion. This move strengthens Merck's ophthalmology presence and bolsters its pipeline with promising candidates, including a late-stage drug for macular degeneration expected to enter a pivotal trial later this year.

Read full article here.